VCP
ABBV icon

Verus Capital Partners’s AbbVie ABBV Stock Holding History

Verus Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1M Sell
47,929
-5,215
-10% -$1.12M 0.65% 32
2026
Q1 		$11.6M Sell
53,144
-2,462
-4% -$546K 0.79% 29
2025
Q4 		$12.7M Sell
55,606
-925
-2% -$211K 0.85% 20
2025
Q3 		$13.1M Sell
56,531
-1,340
-2% -$273K 1.02% 17
2025
Q2 		$10.7M Sell
57,871
-905
-2% -$168K 0.96% 18
2025
Q1 		$12.3M Sell
58,776
-2,109
-3% -$410K 1.23% 13
2024
Q4 		$10.8M Sell
60,885
-1,087
-2% -$200K 1.03% 15
2024
Q3 		$12.2M Sell
61,972
-629
-1% -$117K 1.19% 14
2024
Q2 		$10.7M Sell
62,601
-2,039
-3% -$338K 1.11% 15
2024
Q1 		$11.8M Buy
64,640
+990
+2% +$171K 1.3% 13
2023
Q4 		$9.86M Sell
63,650
-1,445
-2% -$211K 1.21% 16
2023
Q3 		$9.7M Sell
65,095
-11,540
-15% -$1.69M 1.35% 12
2023
Q2 		$10.3M Sell
76,635
-12,402
-14% -$1.82M 1.46% 11
2023
Q1 		$14.2M Buy
89,037
+6,300
+8% +$963K 2.22% 8
2022
Q4 		$13.4M Sell
82,737
-5,043
-6% -$773K 2.51% 8
2022
Q3 		$11.8M Buy
87,780
+24,606
+39% +$3.53M 2.22% 8
2022
Q2 		$14.6M Sell
63,174
-34,590
-35% -$5.29M 2.86% 6
2022
Q1 		$15M Buy
+97,764
New +$14.2M 2.33% 7
2020
Q1 		$1.54M Buy
20,282
+3,758
+23% +$320K 0.49% 38
2019
Q4 		$1.46M Buy
+16,524
New +$1.37M 0.48% 35

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Verus Capital Partners's ABBV Position: Q2 2026 in Review

Verus Capital Partners reduced its AbbVie (ABBV) stake by 9.8% in Q2 2026, selling an estimated $1.12M and leaving 47,929 shares worth $12.1M. The position accounts for 0.65% of the portfolio, ranked #32.

Verus Capital Partners first reported a position in ABBV in Q4 2019 and has held it in 20 quarters since. The position peaked at $15M in Q1 2022. 4,216 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Verus Capital Partners held 47,929 shares of AbbVie worth $12.1M as of Q2 2026.
  • Verus Capital Partners sold 5,215 AbbVie shares in Q2 2026, an estimated $1.12M.
  • AbbVie made up 0.65% of Verus Capital Partners's portfolio in Q2 2026, its #32 holding.
  • Verus Capital Partners first reported a position in AbbVie in Q4 2019 and has held it in 20 quarters since.
  • Verus Capital Partners's AbbVie position peaked at $15M in Q1 2022.
  • 4,216 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Verus Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.